Discharge of post-lymphatic filariasis surveillance programme

Discharge of post-lymphatic filariasis surveillance programme

The Ministry of Health recently issued the "National Work Plan for the Monitoring of Lymphatic Filariasis Elimination", which requires all localities to implement it in a conscientious manner and promptly identify potential and imported sources of infection so as to prevent the reintroduction of filariasis.

The "Proposal" proposes that all types of medical institutions, disease prevention and control institutions, medical personnel, quarantine personnel, and disease control personnel should, after discovering suspected suspected filariasis cases, clinically diagnosed cases, and confirmed cases, report the disease surveillance information within 24 hours. The management system reports. Units that do not have the conditions for reporting online immediately shall send (send) an infectious disease report card to the county-level disease control center within 24 hours after diagnosis. The county-level CDC shall immediately report online after receiving the infectious disease report card. For microfilaria positive cases confirmed to be imported from outside the country, blood tests for microfilaria in the same batch of returning personnel are required. For some heavily populated areas with remote locations, inconvenient traffic, and relatively weak prevention and treatment work, provincial disease control agencies may carry out irregular surveys based on local conditions to identify possible sources of infection.

The "Proposal" proposes that the natural villages with more than one case of microfilaria positive should be investigated and controlled by pathogens and media. For cases identified as sources of imported infections, provincial disease control agencies are responsible for organizing media investigations on the places where the same returnees are located. If mosquitoes infected with larvae are found, they must carry out appropriate anti-mosquito efforts.

The "Programme" clearly states that the Ministry of Health is responsible for the organization and leadership of the country after the elimination of filariasis surveillance work, and the health administrative departments at all levels are responsible for organizing, leading and coordinating post-filariasis surveillance in the region. The China CDC is responsible for the organization, coordination, and technical guidance of post-filariasis surveillance in the country. Provincial-level disease control agencies are responsible for the specific implementation of post-filariasis surveillance in the province (region, city). The county-level disease control agency is responsible for reporting blood sample collection and case investigation of the cases, and assisting the provincial disease control agencies to conduct case investigations and Epidemic point processing and other related work.

Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
It was reviewed and approved under the Food and Drug Administration`s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer.
We produce a series of complete intermediates for Palbociclib, intermediate I (CAS No. 571188-59-5), intermediate II (CAS No. 1013916-37-4) and intermediate III (CAS No. 1016636-76-2) etc.

All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.

Pharmaceutical Intermediates

Palbociclib Intermediates

Palbociclib Intermediates,Cas 571188-59-5,Cas 1013916-37-4,Cas 1016636-76-2

Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com